Cannabis for Opioid Withdrawal Linked to Reduced Opioid Use in Study

People who used cannabis to blunt the symptoms of opioid withdrawal were more than twice as likely to report cutting back on opioids, according to a study of 197 people who use unregulated drugs in Vancouver. The association, published in the Journal of Cannabis Research, was far stronger among participants living with moderate to severe pain, who had roughly six times the odds of reporting reduced opioid use.

The finding is drawn from a one-time survey, not a controlled trial, and the researchers are careful about what it can and cannot show. It cannot establish that cannabis caused anyone to use fewer opioids. What it does is attach a number to something people who use drugs have described for years — that reaching for cannabis during withdrawal seems, to them, to take the edge off the compulsion to use again — and it points to pain as the factor that may separate the people it helps from the people it does not.

What the survey measured

The data come from a cross-sectional questionnaire given to cannabis-using participants in two long-running Vancouver cohorts of people who use unregulated opioids, administered between December 2019 and November 2021. Of the 197 people included, 89 — about 45 percent — said they had used cannabis to manage opioid withdrawal symptoms in the previous six months. Among that group, most reported that cannabis let them get by on less: roughly two-thirds said they did not need as much of their opioid when they used cannabis, and 57 percent of the full sample said they used fewer opioids during periods of cannabis use.

Running those responses through a multivariable model that adjusted for age, gender, race and pain, the team at the British Columbia Centre on Substance Use found that using cannabis for withdrawal was associated with more than double the odds of self-reported reductions in opioid use — an adjusted odds ratio of 2.16. The authors describe it as the first quantitative analysis to look specifically at whether people who deliberately use cannabis for withdrawal go on to consume fewer opioids, as opposed to the narrower question of whether cannabis eases individual symptoms like pain or insomnia.

Why pain changes the picture

The most striking number is in the subgroup analysis. When the researchers split participants by whether they lived with moderate to severe pain, the association held only for those in pain — and there it was much larger, an adjusted odds ratio of 6.55. Among participants without significant pain, cannabis use for withdrawal showed no statistically significant link to cutting back.

That pattern fits a straightforward hypothesis. Pain is common among people who use unregulated opioids and is one of the reasons opioid use persists; if cannabis is doing part of the analgesic work, it could loosen the grip of the pain that keeps someone using. The authors stop short of claiming that mechanism, and the confidence interval around the 6.55 figure is wide — stretching from about 2.4 to nearly 20 — which reflects how few people sit in that subgroup. But the signal is consistent with a growing body of work on cannabis and pain, and it is the part of the study most likely to shape what a future trial would test.

Withdrawal is where relapse and overdose cluster

The reason any of this matters is timing. Withdrawal is the point at which attempts to stop or cut back most often collapse, and the period right after a break in use carries an elevated risk of overdose because tolerance has dropped. Anything that makes withdrawal more bearable has a plausible path to reducing harm, which is why the question is worth studying rather than dismissing.

None of this positions cannabis as a substitute for the treatments with the strongest evidence. Buprenorphine and methadone remain the front-line medications for opioid addiction, with decades of data showing they cut overdose deaths and keep people in care. The study's own authors frame cannabis as a possible adjunct for a specific problem — getting through withdrawal — not as a stand-alone therapy, and the participants were describing what they already do on their own, outside any clinical program.

The limits are substantial

The caveats here are not fine print; they define how much weight the result can bear. Because the survey captured cannabis use and opioid use at the same moment, it cannot say which came first, and self-reported reductions are vulnerable to recall and to the natural tendency to credit a chosen coping strategy. The sample is small, and the data were collected in 2019 through 2021, before the current, more volatile phase of the unregulated supply. Vancouver's drug market and harm-reduction environment also differ from most of the United States, so the numbers should not be read as directly transferable. The questionnaire did not capture how much cannabis people used, how they used it, or which cannabinoids were involved — details that would matter enormously to any clinical application.

The researchers are explicit that their work is a reason to run experimental trials of cannabinoids for withdrawal in people living with pain, not evidence that clinicians should start recommending cannabis. That distinction is the whole point.

A conflict worth naming

There is also a disclosure that belongs in the foreground rather than the footnotes. The study's senior author holds a professorship in cannabis science at the University of British Columbia that was created with arm's-length gifts to the university from a licensed cannabis producer and the provincial government, and another author reported paid consulting for a medical cannabis company. The core funding came from the U.S. National Institutes of Health and the Canadian Institutes of Health Research, and the industry ties do not by themselves invalidate the analysis. But cannabis research carries a persistent tension between enthusiasm and evidence, and readers are entitled to weigh who paid for the work.

It is also worth remembering that cannabis is not consequence-free. Marijuana dependence is real, more common in people who use it heavily and daily, and the same population that might benefit from cannabis during withdrawal is one in which layering a second substance deserves caution. A finding that cannabis helps some people use fewer opioids and a finding that cannabis can become a problem in its own right are not contradictory; both can be true, which is exactly why the authors are asking for trials rather than declaring an answer.